A SECRET WEAPON FOR SEMAGLUTIDE 5 MG VIALS

The trial obtained equally its Major endpoints, with semaglutide 2.4 mg demonstrating statistically substantial and remarkable improvements in liver fibrosis without having worsening of steatohepatitis, in addition to resolution of steatohepatitis without any worsening of liver fibrosis in those with MASH compared to placebo.1Other Techniques to ha